Skip to content
Clinical Trials – home

NBR Polska Tomasz Klodawski

Verified siteinfo

Poland Aleja Wincentego Witosa 31, 00-710 Warsaw, Poland

  • 2 trials recruiting
  • Obesity · Overweight · Type 2 diabetes mellitus
  • Adult patients

About Specializations

NBR Polska Tomasz Klodawski in Warsaw, Poland specialises in clinical trials of conditions such as Obesity, Overweight, Type 2 diabetes mellitus, Arteriosclerosis, and other specialisations. This site conducts important research.

Main research areas of the site

Chronic Pain Management

The medical center is at the forefront of research in chronic pain management, particularly focusing on conditions such as diabetic peripheral neuropathy (DPN). The ongoing studies aim to evaluate the efficacy of novel treatments like ODM-111, which are designed to alleviate the persistent pain associated with this condition.

  • Diabetic Peripheral Neuropathy
  • Innovative Pain Therapies
  • Patient-Centric Approaches

Through these efforts, the center contributes significantly to improving the quality of life for patients suffering from chronic pain, offering new hope through advanced therapeutic options.

Autoimmune Disorders

Specializing in the study of Sjögren’s Syndrome, the center is dedicated to understanding and treating this complex autoimmune disorder. Research involving HZN-1116 is focused on addressing both systemic manifestations and patient-reported symptoms, providing a comprehensive approach to managing the disease.

  • Sjögren’s Syndrome
  • Systemic Disease Management
  • Symptom Relief Strategies

The center's work in this area is pivotal in developing targeted therapies that can significantly enhance patient outcomes and manage the multifaceted symptoms of autoimmune conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Aleja Wincentego Witosa 3100-710 WarsawPoland
Recruiting now
2 trials
Conditions studied
7
Partner status
Verified site

More sites in WarsawPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

8 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
  • Sponsor:Novo Nordisk A/S

Obesity+1

Recruiting

Efficacy and safety of oral semaglutide for weight loss in adults with overweight or obesity

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

A study testing cagrilintide and semaglutide compared to placebo in people with type 2 diabetes not well controlled by diet and exercise

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Obesity+1

Not recruiting

Study of cagrilintide for weight reduction in adults with overweight or obesity when combined with lifestyle changes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Study on How Insulin Icodec and Semaglutide Help Control Blood Sugar in Patients with Type 2 Diabetes

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Icodec
  • Sponsor:Novo Nordisk A/S

Diabetic neuropathy+1

Not recruiting

Study on the Effectiveness of ODM-111 and Paracetamol for Chronic Pain in Patients with Diabetic Peripheral Neuropathy

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:ODM-111
  • Sponsor:Orion Corporation
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.